Several brokerages have updated their recommendations and price targets on shares of Seres Therapeutics (NASDAQ: MCRB) in the last few weeks:

  • 8/11/2017 – Seres Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/8/2017 – Seres Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
  • 8/4/2017 – Seres Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock, up previously from $15.00.
  • 8/3/2017 – Seres Therapeutics was given a new $20.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 8/1/2017 – Seres Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 7/25/2017 – Seres Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/14/2017 – Seres Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $12.00 price target on the stock. According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
  • 7/12/2017 – Seres Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
  • 7/5/2017 – Seres Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $13.00 price target on the stock. According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Seres Therapeutics, Inc. (NASDAQ:MCRB) traded up 0.74% on Thursday, reaching $13.60. The company’s stock had a trading volume of 19,731 shares. Seres Therapeutics, Inc. has a 1-year low of $8.85 and a 1-year high of $15.09. The stock has a 50 day moving average price of $12.69 and a 200-day moving average price of $10.77. The company’s market capitalization is $550.96 million.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.59) by $0.10. The firm had revenue of $3 million for the quarter, compared to analyst estimates of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The firm’s revenue was up .0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.70) EPS. Equities analysts predict that Seres Therapeutics, Inc. will post ($2.48) earnings per share for the current fiscal year.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.